In the phase III HERA trial, adjuvant trastuzumab followed by chemotherapy showed less benefit for HER2-positive breast cancer patients with ER-positive tumors and who had a low FISH ratio (≥ 2 to < 5) [25]. This evidence concerns the gene ERBB2 and breast cancer.